These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1871805)
1. Cyclosporine-associated seizures in bone marrow transplant recipients given busulfan and cyclophosphamide preparative therapy. Ghany AM; Tutschka PJ; McGhee RB; Avalos BR; Cunningham I; Kapoor N; Copelan EA Transplantation; 1991 Aug; 52(2):310-5. PubMed ID: 1871805 [TBL] [Abstract][Full Text] [Related]
2. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682 [TBL] [Abstract][Full Text] [Related]
3. Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen. Kalaycioglu ME; Bolwell BJ Bone Marrow Transplant; 1994 Jul; 14(1):113-5. PubMed ID: 7951097 [TBL] [Abstract][Full Text] [Related]
4. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. Schultz KR; Ratanatharathorn V; Abella E; Eisenbrey AB; Karanes C; Lum LG; de Planque MM; Uberti JP; Ravindranath Y; Sensenbrenner LL Bone Marrow Transplant; 1994 Jun; 13(6):817-22. PubMed ID: 7920320 [TBL] [Abstract][Full Text] [Related]
5. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089 [TBL] [Abstract][Full Text] [Related]
6. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282 [TBL] [Abstract][Full Text] [Related]
7. A comparative trial of posttransplant immunosuppression in patients transplanted for thalassemia. Cyclosporine alone versus cyclosporine, cyclophosphamide, and methotrexate. Galimberti M; Polchi P; Lucarelli G; Giardini C; Baronciani D; Angelucci E; Politi P Transplantation; 1988 Mar; 45(3):566-9. PubMed ID: 3279581 [TBL] [Abstract][Full Text] [Related]
8. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342 [TBL] [Abstract][Full Text] [Related]
9. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192 [TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation from matched related donors for patients with Fanconi anemia using low-dose busulfan and cyclophosphamide as conditioning. Torjemane L; Ladeb S; Ben Othman T; Abdelkefi A; Lakhal A; Ben Abdeladhim A Pediatr Blood Cancer; 2006 Apr; 46(4):496-500. PubMed ID: 16333862 [TBL] [Abstract][Full Text] [Related]
12. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide. Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619 [TBL] [Abstract][Full Text] [Related]
13. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. Zimmer WE; Hourihane JM; Wang HZ; Schriber JR AJNR Am J Neuroradiol; 1998 Apr; 19(4):601-8; discussion 609-10. PubMed ID: 9576643 [TBL] [Abstract][Full Text] [Related]
14. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Ringdén O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC Br J Haematol; 1996 Jun; 93(3):637-45. PubMed ID: 8652385 [TBL] [Abstract][Full Text] [Related]
15. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Reece DE; Frei-Lahr DA; Shepherd JD; Dorovini-Zis K; Gascoyne RD; Graeb DA; Spinelli JJ; Barnett MJ; Klingemann HG; Herzig GP Bone Marrow Transplant; 1991 Nov; 8(5):393-401. PubMed ID: 1768975 [TBL] [Abstract][Full Text] [Related]